Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Meta Expands AI Training With Employee Activity Tracking Tools 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SAN DIEGO, Feb. 23, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016 at 11:20 a.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's marketed products, Chenodal®, Cholbam® and Thiola®.
Retrophin.com
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
